{
  "ticker": "ACRS",
  "company_name": "Aclaris Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02260180",
      "title": "Study of A-101 for the Treatment of Seborrheic Keratosis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Seborrheic Keratosis",
      "start_date": "2014-10",
      "completion_date": "2015-03",
      "enrollment": 0,
      "sponsor": "Aclaris Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03585296",
      "title": "A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Atopic Dermatitis",
      "start_date": "2018-07-10",
      "completion_date": "2019-04-25",
      "enrollment": 0,
      "sponsor": "Aclaris Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05511519",
      "title": "Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Psoriatic Arthritis",
      "start_date": "2022-07-12",
      "completion_date": "2024-01-03",
      "enrollment": 0,
      "sponsor": "Aclaris Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03315689",
      "title": "Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Alopecia Universalis (AU), Alopecia Totalis (AT)",
      "start_date": "2017-12-14",
      "completion_date": "2019-06-20",
      "enrollment": 0,
      "sponsor": "Aclaris Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04524858",
      "title": "Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Cryopyrin-Associated Periodic Syndrome",
      "start_date": "2020-10-23",
      "completion_date": "2021-02-25",
      "enrollment": 0,
      "sponsor": "Aclaris Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03354637",
      "title": "A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Alopecia Areata",
      "start_date": "2017-11-29",
      "completion_date": "2019-09-10",
      "enrollment": 0,
      "sponsor": "Aclaris Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03594227",
      "title": "ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Alopecia",
      "start_date": "2018-06-11",
      "completion_date": "2019-06-18",
      "enrollment": 0,
      "sponsor": "Aclaris Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06374459",
      "title": "Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer",
      "start_date": "2025-01-30",
      "completion_date": "2032-05-31",
      "enrollment": 0,
      "sponsor": "Washington University School of Medicine"
    },
    {
      "nct_id": "NCT03468855",
      "title": "A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Vitiligo",
      "start_date": "2018-03-19",
      "completion_date": "2019-10-16",
      "enrollment": 0,
      "sponsor": "Aclaris Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03224598",
      "title": "A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Dermatosis Papulosa Nigra",
      "start_date": "2017-06-26",
      "completion_date": "2019-01-08",
      "enrollment": 0,
      "sponsor": "Aclaris Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 36,
    "by_phase": {
      "PHASE2": 24,
      "PHASE1, PHASE2": 2,
      "PHASE3": 6,
      "PHASE4": 2,
      "PHASE1": 2
    },
    "by_status": {
      "COMPLETED": 28,
      "TERMINATED": 4,
      "RECRUITING": 3,
      "WITHDRAWN": 1
    },
    "active_trials": 3,
    "completed_trials": 28,
    "conditions": [
      "Advanced Solid Tumor, Advanced Solid Tumor Malignancies",
      "Alopecia",
      "Alopecia Areata",
      "Alopecia Areata, Alopecia Totalis, Alopecia Universalis",
      "Alopecia Areata, Alopecia Universalis, Alopecia Totalis",
      "Alopecia Universalis (AU), Alopecia Totalis (AT)",
      "Androgenetic Alopecia",
      "Atopic Dermatitis",
      "Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema",
      "Common Wart",
      "Common Warts",
      "Cryopyrin-Associated Periodic Syndrome",
      "Dermatosis Papulosa Nigra",
      "Hidradenitis Suppurativa",
      "Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer",
      "Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas",
      "Psoriatic Arthritis",
      "Rheumatoid Arthritis",
      "Rosacea",
      "Seborrheic Keratosis",
      "Seborrheic Keratosis (SK)",
      "Vitiligo"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:15:59.685834",
    "search_query": "Aclaris Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Aclaris+Therapeutics,+Inc."
  }
}